glp-1 impact on food and beverage sales 2025 report drugs are rewriting America's preferences, says IFF GLP-1 Weight-Loss Drugs Ride Health,

Ahrn B (2001) Inhibition of dipeptidyl peptidase-4 (DPP-4): a target to treat type 2 diabetes

23431 (May 1, 2026), the FDA proposed to restrict large-scale 503B compounding of these medications, with a public comment period open through June 29, 2026

Brandt, S

The GIP receptor pathway Glucose-dependent insulinotropic polypeptide is secreted by K-cells in the proximal small intestine

In 2024, the FDA approved Zepbound as the first GLP-1 medication specifically indicated to treat obstructive sleep apnea (OSA) in adults with obesity

As Ozempic and Wegovy continue to be popular choices for managing diabetes and obesity, the ongoing research into their side effects like gastroparesis will remain a critical component of patient care